KR102566845B1 - Anti-met 항체 및 그 용도 - Google Patents

Anti-met 항체 및 그 용도 Download PDF

Info

Publication number
KR102566845B1
KR102566845B1 KR1020227005547A KR20227005547A KR102566845B1 KR 102566845 B1 KR102566845 B1 KR 102566845B1 KR 1020227005547 A KR1020227005547 A KR 1020227005547A KR 20227005547 A KR20227005547 A KR 20227005547A KR 102566845 B1 KR102566845 B1 KR 102566845B1
Authority
KR
South Korea
Prior art keywords
antibody
human
met
antigen
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020227005547A
Other languages
English (en)
Korean (ko)
Other versions
KR20220030306A (ko
Inventor
파올로 미첼리
Original Assignee
아곰앱 테라퓨틱스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아곰앱 테라퓨틱스 filed Critical 아곰앱 테라퓨틱스
Priority to KR1020237027102A priority Critical patent/KR102686694B1/ko
Publication of KR20220030306A publication Critical patent/KR20220030306A/ko
Application granted granted Critical
Publication of KR102566845B1 publication Critical patent/KR102566845B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/528—CH4 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
KR1020227005547A 2016-06-27 2017-06-23 Anti-met 항체 및 그 용도 Active KR102566845B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237027102A KR102686694B1 (ko) 2016-06-27 2017-06-23 Anti-met 항체 및 그 용도

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB1611123.9 2016-06-27
GBGB1611123.9A GB201611123D0 (en) 2016-06-27 2016-06-27 Anti met antibodiesand uses thereof
KR1020197002631A KR102366667B1 (ko) 2016-06-27 2017-06-23 Anti-met 항체 및 그 용도
PCT/EP2017/065599 WO2018001909A1 (en) 2016-06-27 2017-06-23 Anti-met antibodies and uses thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020197002631A Division KR102366667B1 (ko) 2016-06-27 2017-06-23 Anti-met 항체 및 그 용도

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237027102A Division KR102686694B1 (ko) 2016-06-27 2017-06-23 Anti-met 항체 및 그 용도

Publications (2)

Publication Number Publication Date
KR20220030306A KR20220030306A (ko) 2022-03-10
KR102566845B1 true KR102566845B1 (ko) 2023-08-14

Family

ID=56891586

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020227005547A Active KR102566845B1 (ko) 2016-06-27 2017-06-23 Anti-met 항체 및 그 용도
KR1020197002631A Active KR102366667B1 (ko) 2016-06-27 2017-06-23 Anti-met 항체 및 그 용도
KR1020237027102A Active KR102686694B1 (ko) 2016-06-27 2017-06-23 Anti-met 항체 및 그 용도

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020197002631A Active KR102366667B1 (ko) 2016-06-27 2017-06-23 Anti-met 항체 및 그 용도
KR1020237027102A Active KR102686694B1 (ko) 2016-06-27 2017-06-23 Anti-met 항체 및 그 용도

Country Status (13)

Country Link
US (3) US11098126B2 (enExample)
EP (2) EP3475302A1 (enExample)
JP (3) JP7088853B2 (enExample)
KR (3) KR102566845B1 (enExample)
CN (3) CN120005025A (enExample)
AU (2) AU2017288985B2 (enExample)
BR (1) BR112018077139A8 (enExample)
CA (2) CA3032496A1 (enExample)
GB (1) GB201611123D0 (enExample)
MX (1) MX2019000135A (enExample)
NZ (4) NZ789717A (enExample)
RU (2) RU2765267C2 (enExample)
WO (1) WO2018001909A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT201800000534A1 (it) * 2018-01-03 2019-07-03 Procedimenti per la promozione della crescita cellulare degli isolotti pancreatici.
GB201611123D0 (en) 2016-06-27 2016-08-10 Euremab Srl Anti met antibodiesand uses thereof
IT201800000535A1 (it) 2018-01-03 2019-07-03 Procedimenti per la cura del cancro.
KR102221755B1 (ko) * 2018-05-02 2021-03-02 (주)에임드바이오 c-Met에 특이적으로 결합하는 항체 및 그의 용도
SG11202108311RA (en) 2019-02-26 2021-09-29 Janssen Biotech Inc Combination therapies and patient stratification with bispecific anti-egfr/c-met antibodies
US11879013B2 (en) 2019-05-14 2024-01-23 Janssen Biotech, Inc. Combination therapies with bispecific anti-EGFR/c-Met antibodies and third generation EGFR tyrosine kinase inhibitors
JOP20220184A1 (ar) 2020-02-12 2023-01-30 Janssen Biotech Inc علاج مصابي السرطان ممن لديهم طفرات تخطي c-Met إكسون14
JP2024515266A (ja) 2021-04-08 2024-04-08 ビョンディス・ビー．ブイ． 抗ｃ－ＭＥＴ抗体及び抗体薬物複合体
EP4340937A1 (en) 2021-05-21 2024-03-27 Emblation Limited Microwave treatment of tissue
WO2025163490A1 (en) * 2024-01-30 2025-08-07 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Growth factor receptor agonist/antagonist

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998000543A1 (en) * 1996-07-03 1998-01-08 Genentech, Inc. Hepatocyte growth factor receptor agonists and uses thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US5587309A (en) 1994-04-29 1996-12-24 The United States Of America As Represented By The Department Of Health And Human Services Method of stimulating proliferation and differentiation of human fetal pancreatic cells ex vivo
US5686292A (en) 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
WO2001093899A1 (en) 2000-06-02 2001-12-13 Hiroshi Okamoto PANCREATIC LANGERHANS β CELL PROLIFERATION PROMOTER AND APOPTOSIS INHIBITOR, AND SCREENING OF CANDIDATE COMPOUNDS FOR THE E DRUGS
GB0110430D0 (en) 2001-04-27 2001-06-20 Medical Res Council Protein variants and uses thereof
PL204899B1 (pl) 2001-05-23 2010-02-26 Bristol Myers Squibb Co Zastosowanie rozpuszczalnej zmutowanej cząsteczki CTLA4
ITMI20031127A1 (it) 2003-06-05 2004-12-06 Uni Degli Studi Del Piemont E Orientale Am Anticorpi anti-hgf-r e loro uso
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
JP5068651B2 (ja) * 2004-08-05 2012-11-07 ジェネンテック， インコーポレイテッド ヒト化抗ｃｍｅｔ抗体
DK1981981T3 (da) * 2006-02-06 2011-09-26 Metheresis Translational Res Sa Monoklonalt anti-met antistof, fragmenter og vektorer deraf til behandling af tumorer, samt tilsvarende produkter
AU2011203499B2 (en) 2006-03-30 2013-01-31 Novartis Ag Compositions and methods of use for antibodies of c-Met
WO2008111464A1 (ja) * 2007-03-05 2008-09-18 Eisai R & D Management Co., Ltd. スプライシング異常を指標とする抗ガン剤の作用検定方法
GB2461546B (en) 2008-07-02 2010-07-07 Argen X Bv Antigen binding polypeptides
US20120190668A1 (en) 2009-08-12 2012-07-26 Oehlen Lambertus J W M Enhancement of cellular transplantation using small moleucle modulators of hepatocyte growth factor (scatter factor) activity
GB2476681B (en) 2010-01-04 2012-04-04 Argen X Bv Humanized camelid VH, VK and VL immunoglobulin domains
WO2011150454A1 (en) * 2010-06-01 2011-12-08 Monash University ANTIBODIES DIRECTED TO THE UNPROCESSED RECEPTOR TYROSINE KINASE c-MET
BR122014027420A2 (pt) * 2010-11-03 2019-08-20 Argenx Bvba Anticorpos anti c-met
DK2686347T3 (en) * 2011-03-16 2018-06-25 Argenx Bvba Antibodies against CD70
WO2012138599A2 (en) 2011-04-02 2012-10-11 Washington State University Research Foundation Hepatocyte growth factor mimics as therapeutic agents
KR101444837B1 (ko) 2011-06-03 2014-09-30 한국생명공학연구원 ＨＧＦ 활성을 가지는 ｃ-Ｍｅｔ에 대한 인간항체 및 이의 용도
KR20130036993A (ko) 2011-10-05 2013-04-15 삼성전자주식회사 ｃ-Ｍｅｔ의 ＳＥＭＡ 도메인 내의 에피토프에 특이적으로 결합하는 항체
GB201121914D0 (en) * 2011-12-20 2012-02-01 Ge Healthcare Ltd Method for patient selection
WO2013175276A1 (en) * 2012-05-23 2013-11-28 Argen-X B.V Il-6 binding molecules
KR101615619B1 (ko) 2014-08-07 2016-04-26 주식회사 파멥신 c-Met 특이적 인간 항체 및 그 제조방법
CA2972048C (en) 2014-12-22 2023-03-07 The Rockefeller University Anti-mertk agonistic antibodies and uses thereof
CN105087468B (zh) 2015-09-01 2018-12-07 东南大学 一种高效诱导干细胞向胰岛β样细胞分化的方法
KR102476846B1 (ko) 2016-02-05 2022-12-12 주식회사 헬릭스미스 항―ｃ―ＭＥＴ 항체 및 이의 용도
IT201800000534A1 (it) 2018-01-03 2019-07-03 Procedimenti per la promozione della crescita cellulare degli isolotti pancreatici.
GB201611123D0 (en) 2016-06-27 2016-08-10 Euremab Srl Anti met antibodiesand uses thereof
IT201800000535A1 (it) 2018-01-03 2019-07-03 Procedimenti per la cura del cancro.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998000543A1 (en) * 1996-07-03 1998-01-08 Genentech, Inc. Hepatocyte growth factor receptor agonists and uses thereof

Also Published As

Publication number Publication date
AU2017288985B2 (en) 2024-05-16
BR112018077139A2 (pt) 2019-04-30
CA3260141A1 (en) 2025-04-16
JP2022121461A (ja) 2022-08-19
KR102686694B1 (ko) 2024-07-22
US20190315873A1 (en) 2019-10-17
US20240228632A9 (en) 2024-07-11
MX2019000135A (es) 2019-09-26
EP3674321A2 (en) 2020-07-01
US20220153850A1 (en) 2022-05-19
CA3032496A1 (en) 2018-01-04
NZ789725A (en) 2025-11-28
CN109689687B (zh) 2022-07-15
US20240132601A1 (en) 2024-04-25
KR102366667B1 (ko) 2022-02-23
KR20220030306A (ko) 2022-03-10
JP7546834B2 (ja) 2024-09-09
US12084504B2 (en) 2024-09-10
RU2765267C2 (ru) 2022-01-27
BR112018077139A8 (pt) 2022-12-13
KR20230120678A (ko) 2023-08-17
KR20190025938A (ko) 2019-03-12
EP3475302A1 (en) 2019-05-01
RU2018146419A3 (enExample) 2020-09-30
EP3674321A3 (en) 2020-09-30
WO2018001909A1 (en) 2018-01-04
NZ789721A (en) 2025-11-28
NZ749578A (en) 2025-11-28
JP7088853B2 (ja) 2022-06-21
NZ789717A (en) 2025-11-28
US11098126B2 (en) 2021-08-24
RU2018146419A (ru) 2020-06-26
CN115057933B (zh) 2025-02-18
GB201611123D0 (en) 2016-08-10
JP2024096330A (ja) 2024-07-12
CN115057933A (zh) 2022-09-16
JP2019524085A (ja) 2019-09-05
CN120005025A (zh) 2025-05-16
RU2022101369A (ru) 2022-02-08
CN109689687A (zh) 2019-04-26
AU2017288985A1 (en) 2019-01-17
AU2024205680A1 (en) 2024-09-19

Similar Documents

Publication Publication Date Title
KR102566845B1 (ko) Anti-met 항체 및 그 용도
KR20170099918A (ko) 항-axl 길항성 항체
US20110129480A1 (en) Anti-ferroportin 1 monoclonal antibodies and uses thereof
AU2019205516B2 (en) Methods for promoting pancreatic islet cell growth
KR101353117B1 (ko) 항-페로포틴 １ 모노클로날 항체 및 이의 용도
US20210347901A9 (en) Methods for promoting pancreatic islet cell growth
US11834507B2 (en) Anti-MET agonist antibody for use in the treatment of colorectal cancer
NZ789715A (en) Anti-met antibodies and uses thereof

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20220218

Application number text: 1020197002631

Filing date: 20190125

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220318

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220401

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20221117

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20230508

A107 Divisional application of patent
GRNT Written decision to grant
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20230809

Application number text: 1020197002631

Filing date: 20190125

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20230809

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20230809

End annual number: 3

Start annual number: 1

PG1601 Publication of registration